Ivosidenib Tablets are a targeted drug for acute myeloid leukemia (AML) caused by specific gene mutations. Their price varies depending on the manufacturer and specifications. This article will detail the price, indications, and target population of Ivosidenib Tablets to help patients and their families gain a better understanding of this drug.

How much does a box of Ivosidenib Tablets cost?

The price of Ivosidenib Tablets is a key concern for many patients and their families. As an imported drug, its price is significantly affected by the manufacturer and specifications. The following is detailed information about the price of Ivosidenib Tablets.

Manufacturers and Prices

Currently, the commonly available Ivosidenib Tablets on the market are mainly produced by Lucius (Laos). The specification of Lucius' product is 250mg*60 tablets, with a price of approximately 604 US dollars per box. Patients can choose according to their own needs.

Purchasing Channels and Precautions

Ivosidenib Tablets have been launched in China but have not yet been included in medical insurance. Patients can purchase them through hospitals, online pharmacies, formal medical service institutions, or cross-border e-commerce platforms. When purchasing, it is necessary to carefully verify the authenticity of the drug, pay attention to the production date, and avoid buying counterfeit or substandard drugs.

After understanding the price and purchasing channels of Ivosidenib Tablets, patients can plan their treatment costs more rationally. Next, we will discuss the indications of this drug.

Indications of Ivosidenib Tablets

Ivosidenib Tablets are a targeted drug, and their indications are for patients with specific gene mutations. The following is a detailed introduction to their indications.

Indication Scope

Ivosidenib Tablets are indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who carry a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its mechanism of action is to inhibit the activity of the mutant IDH1 enzyme, helping patients control their condition.

Target and Ingredients

The main ingredient of Ivosidenib Tablets is Ivosidenib, and its target of action is IDH1. This targeted therapy can act precisely on the mutant gene, reducing damage to normal cells and improving treatment efficacy.

The indications of Ivosidenib Tablets are clear and highly targeted, providing a new treatment option for specific patients. Next, we will introduce its target population.

Target Population of Ivosidenib Tablets

Ivosidenib Tablets are not suitable for all patients, and their use depends on the specific conditions of the patient. The following is a detailed explanation of the target population.

Medication for Special Populations

For pregnant women, Ivosidenib Tablets may cause harm to the fetus and should be used with caution; lactating women should stop breastfeeding during treatment and for at least 1 month after stopping the drug. No dose adjustment is required for elderly patients, while the safety of the drug in pediatric patients under 18 years of age has not been confirmed.

Patients with Hepatic or Renal Impairment

No dose adjustment is required for patients with mild or moderate hepatic or renal impairment. However, for patients with severe hepatic or renal impairment, the risks and benefits must be carefully evaluated before deciding whether to use the drug.

The target population of Ivosidenib Tablets must strictly follow the doctor's advice to ensure the safety and effectiveness of medication. By understanding the drug's price, indications, and target population, patients can better plan their treatment plans.